New clinical trial data reveals a striking 23% reduction in kidney disease progression among non-diabetic chronic kidney disease patients treated with finerenone compared to placebo. This finding, drawn from multiple Phase 3 randomized controlled trials spanning over 9,400 patients internationally, underscores the drug’s efficacy beyond its originally approved diabetic kidney disease indication.
The significance of this statistic lies in the clinical context: non-diabetic CKD patients have historically lacked targeted pharmacologic interventions beyond standard-of-care agents like ACE inhibitors and angiotensin receptor blockers. Finerenone’s demonstrated 23% relative risk reduction in composite kidney outcomes—including kidney failure, sustained eGFR decline, and renal death—represents a genuine therapeutic advance. Additional cardiovascular benefits, including a 14% reduction in cardiovascular death risk, further strengthen the clinical case for broader patient access to this mineralocorticoid receptor antagonist.
Read the full article on GMJ Newsroom.
Was this article helpful?
